A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Patients were divided into drug class groups and matched by a propensity score 1:1. There were 27,991 pairs to compare SGLT2 inhibitors to DPP-4 inhibitors, 32,107 pairs to compare GLP-1 versus ...

McKesson's strategic growth in oncology, biopharma and tech drives momentum in 2025. Can MCK overcome its sustaining challenges with robust finances and innovation?

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

PepsiCo’s selloff presents the highest dividend yield in history. Find out why PEP stock might mirror the Dotcom bust ...

Ocean demand being pulled forward. The main debate regarding the container ship market is whether several factors will converge to tank rates later this year. Most industry profes ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

Although reports of vision problems with weight loss drugs are still rare, researchers say there is cause for concern because ...

A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

Since the approval of human insulin (Humulin) in 1982, the FDA has approved 59 unique antidiabetic drugs, including 36 new molecular entities and 23 drug combinations.’ The paper is one of ...